← Back to patent-cliff list
Psilocybin（Pilz Bioscience）
Tier C — Watch / tradePsilocybin（Pilz Bioscience）
Pilz Bioscience Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT1A, 5-HT2A
Indications (approved)：Treatment-resistant depression, 脆性X染色体综合征, Mild cognitive impairment, 行为
Regional status
US
Phase III
2024-04-19
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Psilocybin（Pilz Bioscience）?
Approved indications include: Treatment-resistant depression, 脆性X染色体综合征, Mild cognitive impairment, 行为.
When does the Psilocybin（Pilz Bioscience） patent expire?
No public expiry year is available for Psilocybin（Pilz Bioscience） yet; this page updates once verified.
How do I get a quote for Psilocybin（Pilz Bioscience） intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01